Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(29%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
29%
Ph not_applicable
1
14%
Ph phase_3
2
29%
Ph early_phase_1
1
14%
Ph phase_4
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Other(1)

Detailed Status

Recruiting2
Completed2
Enrolling by invitation1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 32 (28.6%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

enrolling_by_invitation114%
recruiting229%
not_yet_recruiting114%
unknown114%
completed229%

Recent Activity

2 active trials
Showing 5 of 7
not_yet_recruitingphase_2

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

NCT07378761
recruitingphase_3

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

NCT07296458
enrolling_by_invitationphase_2

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

NCT06591468
completedearly_phase_1

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

NCT06591455
recruitingnot_applicable

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

NCT07068191
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07378761Phase 2

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

Not Yet Recruiting
NCT07296458Phase 3

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

Recruiting
NCT06591468Phase 2

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

Enrolling By Invitation
NCT06591455Early Phase 1

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

Completed
NCT07068191Not Applicable

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

Recruiting
NCT05416580Phase 3

Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

Unknown
NCT01510860Phase 4

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7